Mind Medicine Raises $92.1 Million Via Bought Deal Financing

Mind Medicine (NEO: MMED) has closed its previously announced bought deal financing, raising nearly double the initial $50.0 million the company initially sought under the offering. The company managed to raise $92.1 million through the raising, bolstering its cash position to $183.0 million.

Units of the company were sold at $4.40 per share under the offering, with a total of 20.9 million units of the company sold. Each unit consists one one subordinating voting share, as well as one half of a subordinate voting share purchase warrant. Each warrant contains an exercise price of $5.75, and is valid for a period of three years from the date of issuance.

An acceleration clause is also present on the warrant, enabling the company to accelerate the expiry of the warrant should the company trade at more than $9.00 per share on a volume weighted basis for a period of five days.

Proceeds from the offering are to be used for the firms digital medicine division, investment into R&D on LSD therapy, study on LSD microdosing, development of products, as well as general working capital and corporate purposes.

Insiders reportedly subscribed to $1.3 million worth of the financing.

Mind Medicine last traded at $3.94 on the Neo Exchange.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Euro Sun: Rovina Copper-Gold Project Secures Some Major Funding

Recommended

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Related News

Mind Medicine To Raise Up To $100 Million Via ATM Financing

Mind Medicine (NEO: MMED) last night announced that it will be conducting a financing. The...

Tuesday, May 17, 2022, 04:59:05 PM

MindMed Launches R(-)-MDMA Program For Autism Spectrum Disorder Symptoms

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, recently launched a program to...

Tuesday, October 26, 2021, 10:35:00 AM

Canaccord Reiterates $1.75 Price Target For Mind Medicine Following Roadshow Event

This morning, Canaccord released a flash update for Mind Medicine (NEO: MMED) with highlights from...

Monday, September 28, 2020, 11:02:24 AM

Mind Medicine To Conduct $25.0 Million Bought Deal Financing

Mind Medicine (CEO: MMED) announced that it will be conducting a bought deal financing this...

Friday, October 9, 2020, 09:01:05 AM

MindMed Starts Dosing Patients In Phase 1 Clinical Study On MDMA-Like Substances

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Tuesday that the...

Wednesday, September 21, 2022, 11:23:00 AM